不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
双难治性慢性淋巴细胞白血病的治疗——一个未满足的临床需求
英文原题：Treatment of Double-Refractory Chronic Lymphocytic Leukemia-An Unmet Clinical Need.
查看英文原题
Treatment of Double-Refractory Chronic Lymphocytic Leukemia-An Unmet Clinical Need.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
近年来，慢性淋巴细胞白血病（CLL）的管理取得了显著改善。靶向B细胞淋巴瘤（BCL-2）和Bruton激酶（BTK）已成为抑制CLL活性的主要策略。这些药物通常耐受性良好，但由于耐药、不良反应和Richter转化，这些治疗会出现停药。既往使用过BTK抑制剂和BCL2的患者群体日益增多，他们受到后续方案的限制。本综述探讨了ibrutinib和venetoclax的耐药机制。此外，我们介绍了为治疗双重难治性CLL而评估的创新方法。
展开英文摘要原文
Recent years have seen significant improvement in chronic lymphocytic leukemia (CLL) management. Targeting B-cell lymphoma (BCL-2) and Bruton's kinase (BTK) have become the main strategies to restrain CLL activity. These agents are generally well tolerated, but the discontinuation of these therapies happens due to resistance, adverse effects, and Richter's transformation.
A growing population of patients who have previously used both BTK inhibitors and BCL2 suffer from the constriction of the following regimens. This review explores the resistance mechanisms for both ibrutinib and venetoclax.
Moreover, we present innovative approaches evaluated for treating double-refractory CLL.
论文信息
- 作者
- Zygmunciak P、Robak T、Puła B
- 单位
- Department of Hematology, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland.Poland
- 文献类型
- 综述
- 期刊
- International journal of molecular sciences2024 Jan 27
- 原文标识
- PubMed 38338868 · DOI 10.3390/ijms25031589
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →